Key Takeaways
- • Lifespan Vision Ventures led Remedium Bio's $10 million Series A financing round, completing the initial closing with co-investors Eli Lilly and HKX Capital.
- • Remedium Bio develops durable protein therapeutics using adipocytes as a production site, designed to deliver multi-year therapeutic benefit via subcutaneous administration for chronic disease treatment.
- • The capital will accelerate advancement of Remedium's lead programs, expand its platform capabilities, and fund preparation for first-in-human clinical studies.
- • Harry Robb of Lifespan Vision Ventures joined Remedium's Board of Directors as part of the financing agreement, signaling active investor participation in governance.
- • Eli Lilly's participation as a co-investor indicates institutional validation of the durable protein platform approach within large pharmaceutical industry circles.
Summary
Lifespan Vision Ventures announced on August 10, 2026, that it is leading a $10 million Series A financing round for Remedium Bio, Inc., with the initial closing completed. The round includes participation from pharmaceutical giant Eli Lilly and Company and HKX Capital. Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors in connection with the investment.
Remedium Bio is developing a durable protein therapeutics platform designed to enable controlled, long-lasting expression of therapeutic proteins through minimally invasive subcutaneous administration. The company's differentiated approach harnesses adipocytes (fat cells) as a durable site for therapeutic protein production, offering the potential to provide multi-year patient benefit with adjustable dosing—a significant advancement over conventional chronic biologic therapies that typically require frequent dosing intervals.
The Series A financing will support three primary objectives: advancement of Remedium's lead programs, continued expansion of its platform technology, and preparation for first-in-human clinical studies. Andrew Worden, Founding Partner of Lifespan Vision Ventures, emphasized the strategic rationale, stating that "Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy," and noted the firm's commitment to supporting the company's transition toward clinical development.
Frank Luppino, Chief Executive Officer of Remedium Bio, highlighted the alignment between investor and company vision: "Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease." This statement underscores market consensus regarding the therapeutic potential of sustained-release protein delivery systems for chronic disease management. The participation of Eli Lilly—one of the world's largest pharmaceutical companies—in the financing round provides significant validation of Remedium's technology platform and suggests potential strategic interest from the broader pharmaceutical industry in durable protein therapeutics development.
Remedium Bio is developing a durable protein therapeutics platform designed to enable controlled, long-lasting expression of therapeutic proteins through minimally invasive subcutaneous administration. The company's differentiated approach harnesses adipocytes (fat cells) as a durable site for therapeutic protein production, offering the potential to provide multi-year patient benefit with adjustable dosing—a significant advancement over conventional chronic biologic therapies that typically require frequent dosing intervals.
The Series A financing will support three primary objectives: advancement of Remedium's lead programs, continued expansion of its platform technology, and preparation for first-in-human clinical studies. Andrew Worden, Founding Partner of Lifespan Vision Ventures, emphasized the strategic rationale, stating that "Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy," and noted the firm's commitment to supporting the company's transition toward clinical development.
Frank Luppino, Chief Executive Officer of Remedium Bio, highlighted the alignment between investor and company vision: "Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease." This statement underscores market consensus regarding the therapeutic potential of sustained-release protein delivery systems for chronic disease management. The participation of Eli Lilly—one of the world's largest pharmaceutical companies—in the financing round provides significant validation of Remedium's technology platform and suggests potential strategic interest from the broader pharmaceutical industry in durable protein therapeutics development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.